Dodge & Cox – ALNY history
- Issuer:
- Alnylam Pharmaceuticals, Inc.
- Quarters tracked:
- 14 (Q4 2023 → Q1 2026)
- Current shares:
- 1,929,253
- Current value:
- $638.33M
- Peak shares:
- 3,811,480 (Q1 2024)
- Overall change:
- -47%
| Quarter | Shares | Value | $/Share | Share Δ | Δ% |
|---|---|---|---|---|---|
| Q1 2026 | 1,929,253 | $638.33M | $330.87 | -35,162 | -2% |
| Q4 2025 | 1,964,415 | $781.15M | $397.65 | -356,815 | -15% |
| Q3 2025 | 2,321,230 | $1.06B | $456.00 | 0 | 0% |
| Q3 2025 | 2,321,230 | $1058.48B | $456000.00 | -875,866 | -27% |
| Q2 2025 | 3,197,096 | $1.04B | $326.09 | 0 | 0% |
| Q2 2025 | 3,197,096 | $1042.54B | $326090.00 | -154,666 | -5% |
| Q1 2025 | 3,351,762 | $905.04M | $270.02 | 0 | 0% |
| Q1 2025 | 3,351,762 | $905.04B | $270020.00 | -188,500 | -5% |
| Q4 2024 | 3,540,262 | $833.06B | $235310.00 | 0 | 0% |
| Q4 2024 | 3,540,262 | $833.06M | $235.31 | -82,273 | -2% |
| Q3 2024 | 3,622,535 | $996.31M | $275.03 | -157,650 | -4% |
| Q2 2024 | 3,780,185 | $918.59M | $243.00 | -31,295 | -1% |
| Q1 2024 | 3,811,480 | $569.63M | $149.45 | +137,170 | +4% |
| Q4 2023 | 3,674,310 | $703.30M | $191.41 | — | NEW |